ReviewJournal of the American Heart Association2026
Atrial Functional Tricuspid Regurgitation as a Valvular Manifestation of Right Atrial Failure.
Review in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional tricuspid regurgitation has traditionally been attributed to right ventricular remodeling secondary to pulmonary hypertension or left-sided heart disease. However, contemporary imaging studies increasingly identify patients with significant tricuspid regurgitation despite preserved right ventricular geometry, characterized instead by marked right atrial (RA) enlargement and tricuspid annular dilation, most commonly in the setting of atrial fibrillation. This phenotype, termed atrial functional tricuspid regurgitation (AF-TR), is typically described as regurgitation caused by isolated annular dilation. However, this description focuses on the structural end point of disease rather than the underlying pathophysiological substrate. Emerging evidence suggests that AF-TR represents a valvular manifestation of RA failure, a right-sided extension of the broader atrial failure syndrome described for the left atrium. In this framework, atrial cardiomyopathy, characterized by atrial fibrosis, electrical instability, and impaired atrial mechanics, first produces dysfunction of RA reservoir, conduit, and contractile function. Progressive loss of atrial-annular coupling and chamber dilation subsequently destabilize tricuspid annular geometry, culminating in functional regurgitation despite preserved ventricular structure. In this review, we synthesize current evidence on the mechanistic relationship between RA cardiomyopathy, RA failure, and AF-TR. We examine the epidemiology and clinical phenotypes of AF-TR, discuss diagnostic approaches emphasizing RA structure and mechanics, use pacing-induced tricuspid dysfunction as an iatrogenic model to illustrate the mechanisms linking atrial failure to AF-TR, and review therapeutic strategies targeting both the atrial substrate and its valvular consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.